Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Daiko Tsusan Co Ltd
TSE:7673
|
JP |
|
IOI Corporation Bhd
KLSE:IOICORP
|
MY |
|
N
|
Novoray Corp
SSE:688300
|
CN |
|
A
|
Aquarius Engines AM Ltd
TASE:AQUA
|
IL |
|
Suse SA
XETRA:SUSE
|
LU |
|
Relia Inc
TSE:4708
|
JP |
|
N
|
NTT UD REIT Investment Corp
TSE:8956
|
JP |
|
M
|
Minox International Group Bhd
KLSE:MINOX
|
MY |
|
C
|
China Southern Power Grid Technology Co Ltd
SSE:688248
|
CN |
|
Malath Cooperative Insurance Company SJSC
SAU:8020
|
SA |
Molecular Partners AG
Operating Expenses
Molecular Partners AG
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Operating Expenses
-CHf55.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Expenses
-$571.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-36%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Expenses
-CHf141.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Expenses
-CHf316.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Expenses
-CHf118.5m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Operating Expenses
-CHf22.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Operating Expenses?
Operating Expenses
-55.4m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Operating Expenses amounts to -55.4m CHF.
What is Molecular Partners AG's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
4%
Over the last year, the Operating Expenses growth was 16%. The average annual Operating Expenses growth rates for Molecular Partners AG have been 8% over the past three years , 4% over the past five years .
